The FDA is currently accepting comments on a draft guideline for osteoporosis treatments, which calls for more research into the long-term effects of drugs on bone quality. Also, the FDA has rejected an application for approval of Apadaz in its current form…
Etanercept Submitted for Chronic, Severe Plaque Psoriasis in Children The U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application for etanercept (Enbrel) for treating pediatric patients with chronic, severe plaque psoriasis.1 The application was submitted in early January 2016 and is based on results of a one-year Phase 3 study with…
NEW YORK (Reuters Health)—Bone resorption increases during pregnancy and continues to be high postpartum, according to new findings using lead testing to measure bone turnover. Researchers also found unexpected evidence that maternal lead burden is transferred to the fetus. “These data confirm calcium balance studies that indicate increased bone resorption throughout pregnancy and lactation,” Dr….
A recent editorial in Arthritis & Rheumatology explored the role of sensitization, not nociception, as a key mechanism of pain for patients with knee OA, as well as inflammation’s role in pain perception. Recent research of synovitis and joint effusion supports the idea that early prevention or treatment of sensitization may be paramount to reducing long-term pain in patients with knee OA…
Recent clinical trials have evaluated the efficacy of GSK3196165, a monoclonal antibody, and fasinumab, a nerve growth factor antibody, in treating patients with osteoarthritis and pain…
A task force of the American Society for Bone and Mineral Research (ASBMR) has released new recommendations delineating the potential benefits and risks of prolonged therapy with oral and IV bisphosphonate therapy and providing guidance on duration of bisphosphonate therapy for postmenopausal osteoporosis.1 The task force makes clear that data and clinical experience on which…
Some patients with epilepsy have a higher risk of fracture due to falls, and some studies have suggested that anti-epileptic drugs may also contribute to the fracture risk. In a recent review, researchers examined if there is a link between epilepsy and osteoporosis, making recommendations to aid future research…
Foot osteoarthritis (OA) of the first metatarsophalangeal (MTP) joint is thought to have biomechanical factors, but its treatments have not been comprehensively tested in clinical trials. In the first study to explore the efficacy of mechanical interventions, researchers compared the effectiveness of foot orthoses and rocker-sole footwear in reducing pain. Both interventions were effective, but the foot orthoses group wore the intervention for significantly more hours than the footwear group…
A recent editorial examined research findings on how low levels of high-density lipoprotein (HDL) in the blood affect bone health, resulting in cartilage dysfunction and the development of osteoarthritis (OA). Authors note that a high-fat diet in mice with HDL deficiency resulted in OA development; thus, they conclude that in patients with metabolic syndrome, HDL may have a causative relationship to OA…
Two studies have shown that romosozumab is effective for increasing bone mineral density in both men and women with osteoporosis. And due to safety concerns, Janssen has dropped out of clinical trials for fulranumab, which is being studied to treat OA pain…